
Kite releases long-term data for cell therapy
Biopharmaceutical company Kite has announced long-term follow up results of two studies for its CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The results of both a three- and two-year follow-up of the company’s ZUMA trial were announced at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. … Read More















